

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
 NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS 4 Apr 09 ZDB will be removed from STN
 NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
 NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
 NEWS 9 Jun 03 New e-mail delivery for search results now available
 NEWS 10 Jun 10 MEDLINE Reload
 NEWS 11 Jun 10 PCTFULL has been reloaded
 NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
 NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
 saved answer sets no longer valid
 NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
 NEWS 15 Jul 30 NETFIRST to be removed from STN
 NEWS 16 Aug 08 CANCERLIT reload
 NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18 Aug 08 NTIS has been reloaded and enhanced
 NEWS 19 Aug 09 JAPIO to be reloaded August 18, 2002

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
 CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
 AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:13:06 ON 11 AUG 2002

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 20:13:13 ON 11 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4
 DICTIONARY FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e omeprazole/cn

E1	1	OMEAPHINE/CN
E2	1	OMEPRAL/CN
E3	1 -->	OMEPRAZOLE/CN
E4	1	OMEPRAZOLE 5-HYDROXYLASE/CN
E5	1	OMEPRAZOLE LITHIUM SALT/CN
E6	1	OMEPRAZOLE MAGNESIUM/CN
E7	1	OMEPRAZOLE PYRIDONE/CN
E8	1	OMEPRAZOLE SODIUM/CN
E9	1	OMEPRAZOLE SODIUM SALT/CN
E10	1	OMEPRAZOLE SULFENIMIDE/CN
E11	1	OMEPRAZOLE SULFIDE/CN
E12	1	OMEPRAZOLE SULFONE/CN

=> s e3

L1 1 OMEPRAZOLE/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 73590-58-6 REGISTRY

CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (+)-Omeprazole

CN 2-[[(3,5-Dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-5-methoxy-1H-benzimidazole

CN Acidex

CN Antra

CN Antra MUPS

CN Audazol

CN Aulcer

CN Belmazol

CN Ceprandal

CN Desec

CN Dizprazol

CN Dudencer

CN Elgam

CN Emeproton

CN Epirazole

CN Gastrimut

CN Gastroloc

CN Gastrozole

CN Gibancer

CN H 168/68

CN Indurgan

CN Inhibitron

CN Inhipump

CN Logastric

CN Lomac

CN Losec

CN Miol

CN Miracid

CN Mopral

CN Ocid

CN Omapren

CN Omebeta 20

CN / Omed
 CN Omedar
 CN OMEP
 CN Omepral
 CN **Omeprazole**
 CN Omeprazon
 CN Omepril
 CN Omezol
 CN Omezzol
 CN Omid
 CN Omisec
 CN Omizac
 CN OMP
 CN Ompanyt
 CN OMZ
 CN Oprax
 CN Opraz
 CN Ozoken


ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

FS 3D CONCORD
 DR 172964-80-6, 131959-78-9
 MF C17 H19 N3 O3 S
 CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT,
 DRUGU, DRUGUPDATES, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, PHAR,
 PHARMASEARCH, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,
 USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2168 REFERENCES IN FILE CA (1967 TO DATE)
 41 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2171 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> e lansoprazole/cn

E1	1	LANSLIDE/CN
E2	1	LANSOPEP/CN
E3	1	--> LANSOPRAZOLE/CN
E4	1	LANSOPRAZOLE SULFONE/CN
E5	1	LANSTAN/CN
E6	1	LANSTER/CN
E7	1	LANSTON/CN
E8	1	LANSUL/CN
E9	1	LANT 6/CN
E10	1	LANTABETULIC ACID/CN
E11	1	LANTADENE/CN
E12	1	LANTADENE A/CN

=> s e3

L2 1 LANSOPRAZOLE/CN

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 103577-45-3 REGISTRY

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (±)-Lansoprazole

CN 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole

CN A 65006

CN AG 1749

CN Agopton

CN Ilsatec

CN Ketian

CN Lancid

CN Lanfast

CN Lanproton

CN Lansopep

CN **Lansoprazole**

CN Lanston

CN Lanz

CN Lanzol 30

CN Lanzopral

CN Lanzor

CN Ogastro

CN PP/K-10

CN Prevacid

CN Promp

CN Prosogan

CN Suprecid

CN Takepron

CN Ulpax

CN Zoton

FS 3D CONCORD

DR 154727-72-7

MF C16 H14 F3 N3 O2 S


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

738 REFERENCES IN FILE CA (1967 TO DATE)

10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

740 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> e pantoprazole/cn

E1 1 PANTOPHYSIN (RAT CLONE PPH.RN)/CN

E2 1 PANTOPON/CN
 E3 1 --> PANTOPRAZOLE/CN
 E4 1 PANTOPRAZOLE SODIUM/CN
 E5 1 PANTOPRAZOLE SODIUM HYDRATE/CN
 E6 1 PANTOPRAZOLE SODIUM SESQUIHYDRATE/CN
 E7 1 PANTOPRIM/CN
 E8 1 PANTOPUR/CN
 E9 1 PANTOPYRANOID A/CN
 E10 1 PANTOPYRANOID B/CN
 E11 1 PANTOPYRANOID C/CN
 E12 1 PANTOSAL-GLUCOSID/CN

=> s e3

L3 1 PANTOPRAZOLE/CN

=> s e3

L4 1 PANTOPRAZOLE/CN

=> d 14

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 102625-70-7 REGISTRY

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole

CN BY 1023

CN **Pantoprazole**

CN SKF 96022

FS 3D CONCORD

DR 154644-14-1

MF C16 H15 F2 N3 O4 S


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

326 REFERENCES IN FILE CA (1967 TO DATE)

11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

329 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> e rabeprazole/cn

E1 1 RABENOSYN-5 (HUMAN) /CN
 E2 1 RABENZAZOLE/CN
 E3 1 --> RABEPRAZOLE/CN
 E4 1 RABEPRAZOLE SODIUM/CN
 E5 1 RABEPRAZOLE-TH/CN
 E6 1 RABI(S) BLACK 6/CN

E7 1 RABI(S) MAROON OH/CN
 E8 1 RABI(S) OCHER TY/CN
 E9 1 RABIB4 PROTEIN (MOUSE CLONE I1 GENE RABIP4 N-TERMINAL FRAGME
 NT)/CN
 E10 1 RABIDANOL/CN
 E11 1 RABISAN/CN
 E12 1 RABISAN, MIXT. CONTG./CN

=> s e3

L5 1 RABEPRAZOLE/CN

=> d 13

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 102625-70-7 REGISTRY

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole

CN BY 1023

CN **Pantoprazole**

CN SKF 96022

FS 3D CONCORD

DR 154644-14-1

MF C16 H15 F2 N3 O4 S


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

326 REFERENCES IN FILE CA (1967 TO DATE)

11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

329 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

28.60

28.81

STN INTERNATIONAL LOGOFF AT 20:16:50 ON 11 AUG 2002

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
 NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS 4 Apr 09 ZDB will be removed from STN
 NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
 NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
 NEWS 9 Jun 03 New e-mail delivery for search results now available
 NEWS 10 Jun 10 MEDLINE Reload
 NEWS 11 Jun 10 PCTFULL has been reloaded
 NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
 NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
 saved answer sets no longer valid
 NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
 NEWS 15 Jul 30 NETFIRST to be removed from STN
 NEWS 16 Aug 08 CANCERLIT reload
 NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18 Aug 08 NTIS has been reloaded and enhanced
 NEWS 19 Aug 09 JAPIO to be reloaded August 18, 2002

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
 CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
 AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:23:32 ON 11 AUG 2002

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 20:23:39 ON 11 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4

DICTIONARY FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e omeprazole/cn

E1	1	OMEAPHINE/CN
E2	1	OMEPRAL/CN
E3	1 -->	OMEPRAZOLE/CN
E4	1	OMEPRAZOLE 5-HYDROXYLASE/CN
E5	1	OMEPRAZOLE LITHIUM SALT/CN
E6	1	OMEPRAZOLE MAGNESIUM/CN
E7	1	OMEPRAZOLE PYRIDONE/CN
E8	1	OMEPRAZOLE SODIUM/CN
E9	1	OMEPRAZOLE SODIUM SALT/CN
E10	1	OMEPRAZOLE SULFENIMIDE/CN
E11	1	OMEPRAZOLE SULFIDE/CN
E12	1	OMEPRAZOLE SULFONE/CN

=> s e3

L1 1 OMEPRAZOLE/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 73590-58-6 REGISTRY

CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (±)-Omeprazole

CN 2-[[(3,5-Dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-5-methoxy-1H-benzimidazole

CN Acidex

CN Antra

CN Antra MUPS

CN Audazol

CN Aulcer

CN Belmazol

CN Ceprandal

CN Desec

CN Dizprazol

CN Dudencer

CN Elgam

CN Emeproton

CN Epirazole

CN Gastrimut

CN Gastroloc

CN Gastrozole

CN Gibancer

CN H 168/68

CN Indurgan

CN Inhibitron

CN Inhipump

CN Logastric

CN Lomac

CN Losec

CN Miol

CN Miracid

CN Mopral

CN Ocid

CN Omapren

CN Omebeta 20

CN Omed
 CN Omedar
 CN OMEP
 CN Omepral
 CN **Omeprazole**
 CN Omeprazon
 CN Omepril
 CN Omezol
 CN Omezzol
 CN Omid
 CN Omisec
 CN Omizac
 CN OMP
 CN Ompanyt
 CN OMZ
 CN Oprax
 CN Opraz
 CN Ozoken

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

FS 3D CONCORD

DR 172964-80-6, 131959-78-9


MF C17 H19 N3 O3 S

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSChem, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2168 REFERENCES IN FILE CA (1967 TO DATE)

41 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

2171 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

6.34

6.55

FILE 'HCAPLUS' ENTERED AT 20:25:06 ON 11 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Aug 2002 VOL 137 ISS 7
FILE LAST UPDATED: 9 Aug 2002 (20020809/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

(FILE 'HOME' ENTERED AT 20:23:32 ON 11 AUG 2002)

FILE 'REGISTRY' ENTERED AT 20:23:39 ON 11 AUG 2002
E OMEPRAZOLE/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 20:25:06 ON 11 AUG 2002

=> s l1

L2 2172 L1

=> s l2 and pd < march 2000
20427023 PD < MARCH 2000
(PD<20000300)

L3 1814 L2 AND PD < MARCH 2000

=> file uspatfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.14

8.69

FILE 'USPATFULL' ENTERED AT 20:25:39 ON 11 AUG 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 8 Aug 2002 (20020808/PD)
FILE LAST UPDATED: 8 Aug 2002 (20020808/ED)
HIGHEST GRANTED PATENT NUMBER: US6430743
HIGHEST APPLICATION PUBLICATION NUMBER: US2002108159
CA INDEXING IS CURRENT THROUGH 8 Aug 2002 (20020808/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 8 Aug 2002 (20020808/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<

```
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 20:23:32 ON 11 AUG 2002)

FILE 'REGISTRY' ENTERED AT 20:23:39 ON 11 AUG 2002

E OMEPRAZOLE/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 20:25:06 ON 11 AUG 2002

L2 2172 S L1

L3 1814 S L2 AND PD < MARCH 2000

FILE 'USPATFULL' ENTERED AT 20:25:39 ON 11 AUG 2002

=> s l1

L4 210 L1

=> s l4 and pd < march 2000

2624453 PD < MARCH 2000

(PD<20000300)

L5 109 L4 AND PD < MARCH 2000

=> d l5, ibib abs fhitr, 1-5

L5 ANSWER 1 OF 109 USPATFULL

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:

2002:115818 USPATFULL

TITLE:

Pharmaceutical formulation comprising a 2-[(2-pyridinyl) methyl] sulfinyl benzimidazole having anti-ulcer activity and a process for the preparation of such formulation

INVENTOR(S):

Henriksen, Kristian Lund, S.o slashed.borg, DENMARK
Kann, Helle, Frederiksberg, DENMARK
S.o slashed.rensen, Karen Eichstedt, Valby, DENMARK
Pedersen, S.o slashed.ren Bols, Hvidovre, DENMARK

PATENT ASSIGNEE(S):

A/S GEA Farmaceutisk Fabrik, Frederiksberg, DENMARK
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391342	B1	20020521
	WO 9948498		19990930
APPLICATION INFO.:	US 2000-646486		20000919 (9)
	<u>WO 1999-DK137</u>		19990317
			20000919 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1998-397	19980320
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Bennett, Rachel M.	
LEGAL REPRESENTATIVE:	Cohen, Pontani, Lieberman & Pavane	


NUMBER OF CLAIMS: 37
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
 LINE COUNT: 763

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Oral pharmaceutical formulation comprising granules having an inert core coated with a layer, comprising a 2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, a separating layer and an enteric coating layer, and a process for the preparation of such formulation using a melt coating technique for the preparation of the benzimidazole containing layer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **73590-58-6**, Omeprazole
 (pharmaceuticals comprising a 2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having antiulcer activity)
 RN 73590-58-6 USPATFULL
 CN 1H-Benzimidazole, 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 109 USPATFULL

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2002:115775 USPATFULL
 TITLE: In situ formation of polymeric material
 INVENTOR(S): Dettmar, Peter William, Hull, UNITED KINGDOM
 Jolliffe, Ian Gordon, Hull, UNITED KINGDOM
 Skaugrud, Oyvind, Mjoendalen, NORWAY
 PATENT ASSIGNEE(S): Reckitt Benckiser Healthcare (UK) Limited, Slough, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391294	B1	20020521
	WO 9909962		19990304
APPLICATION INFO.:	US 2000-485771		20000412 (9)
	WO 1998-GB2410		19980810
			20000412 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-17626	19970821
	GB 1997-17627	19970821

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Page, Thurman K.
 ASSISTANT EXAMINER: Di Nola Baron, Liliana
 LEGAL REPRESENTATIVE: Fish & Richardson P.C.
 NUMBER OF CLAIMS: 15
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
 LINE COUNT: 865

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutically acceptable bio-adhesive coating, film or gel is

formed in situ at a body surface by the reaction of (i) an anionic polymer or triphosphosphate and (ii) a cationic polymer in the presence of water. The two components are supplied either as separate aqueous solutions or in a single non-aqueous formulation, which can be a liquid suspension tablet, capsule or powder.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **73590-58-6**, Omeprazole

(in situ formation of bioadhesive polymeric material)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 109 USPATFULL

Full Text Citing References

ACCESSION NUMBER: 2002:102067 USPATFULL

TITLE: Suppository form comprising an acid-labile active compound

INVENTOR(S): Linder, Rudolf, Konstanz, GERMANY, FEDERAL REPUBLIC OF Dietrich, Rango, Konstanz, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6383510	B1	20020507
	WO 9929299		19990617
APPLICATION INFO.:	US 2000-554079		20000706 (9)
	WO 1998-EP7946		19981208
			20000706 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19754324	19971208
	DE 1998-19822549	19980520

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Kishore, Gollamudi S.
 ASSISTANT EXAMINER: Bennett, Rachel M.
 LEGAL REPRESENTATIVE: Jacobson Holman, PLLC
 NUMBER OF CLAIMS: 29
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
 LINE COUNT: 577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **73590-58-6**, Omeprazole

(oral administration form contg. acid-labile active agent)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 109 USPATFULL

Full Text Citing References

ACCESSION NUMBER: 2002:63891 USPATFULL
 TITLE: Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
 INVENTOR(S): Fujii, Kenji, Akashi, JAPAN
 Yamashita, Katsuji, Kobe, JAPAN
 Hosoe, Kazunori, Takasago, JAPAN
 Hidaka, Takayoshi, Kobe, JAPAN
 PATENT ASSIGNEE(S): Kaneka Corporation, Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362169	B1	20020326
	WO 9943327		19990902
APPLICATION INFO.:	US 2000-622712		20000822 (9)
	WO 1999-JP717		19990217
			20000822 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-42418	19980224
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Weddington, Kevin E.	
LEGAL REPRESENTATIVE:	Armstrong, Westerman & Hattori, LLP	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	583	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Antibacterial compositions comprising (1) a rifamycin derivative represented by the formula (I) or its physiologically acceptable salt, and (2) a proton pump inhibitor (a) or a bismuth preparation (b) wherein the components (1) and (2) are used in such amounts as producing a synergistic effect against Helicobacter pylori, drugs and remedies for digestive organ diseases which contain the antibacterial compositions, process for producing them, and pharmaceutical preparations related to the antibacterial compositions. The compositions can be administered to patients with digestive diseases caused by infection of Helicobacter pylori in a smaller dose and at a lower administration frequency as compared with conventional remedies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **73590-58-6**, Omeprazole
 (antimicrobial compns. contg. rifamycin derivs. with synergistic effect, drugs and remedies for digestive diseases contg. the same, process for the prodn. thereof and prepns. assocd. therewith)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 109 USPATFULL

Full Text Citing References

ACCESSION NUMBER: 2002:39675 USPATFULL
 TITLE: Double capsule for the administration of active principles in multiple therapies
 INVENTOR(S): Sanso, Giovanni, Milan, ITALY
 PATENT ASSIGNEE(S): Axcan Pharma Inc., Quebec, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6350468	B1	20020226
	WO 9930693		19990624
APPLICATION INFO.:	US 2000-581721		20000616 (9)
	WO 1998-EP8167		19981214
			20000616 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1997-MI2788	19971217
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Bennett, Rachel M.	
LEGAL REPRESENTATIVE:	Myers Bigel Sibley & Sajovec P.A.	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	710	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A pharmaceutical dosage form particularly suitable for the administration of active principles in multiple therapies is disclosed. The pharmaceutical dosage form is a double capsule where in an internal capsule is placed inside an external one. Each internal and external capsule includes one or more active principles. A double capsule according to the invention is preferably used in triple or quadruple therapies against the microorganisms *Helicobacter Pylori*. Advantages of this pharmaceutical dosage form consist in providing a simple posology for administration of two and more active principles, allowing the active principles to activate at the right intervals of time and in the preestablished quantities, and preventing interactions between active principles. In a preferred embodiment of the invention, the pharmaceutical dosage form has an external capsule containing bismuth subcitrate and metronidazole, and an internal capsule containing tetracycline and optionally omeprazole, which is used in therapy for eradication of *Helicobacter pylori*.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **73590-58-6**, Omeprazole
 (double capsules for administration of active principles in multiple therapies against *Helicobacter pylori*)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

25.78

34.47

FILE 'REGISTRY' ENTERED AT 20:26:27 ON 11 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4

DICTIONARY FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e lansoprazole/cn

E1	1	LANSLIDE/CN
E2	1	LANSOPEP/CN
E3	1	--> LANSOPRAZOLE/CN
E4	1	LANSOPRAZOLE SULFONE/CN
E5	1	LANSTAN/CN
E6	1	LANSTER/CN
E7	1	LANSTON/CN
E8	1	LANSUL/CN
E9	1	LANT 6/CN
E10	1	LANTABETULIC ACID/CN
E11	1	LANTADENE/CN
E12	1	LANTADENE A/CN

=> s e3

L6 1 LANSOPRAZOLE/CN

=> d 16

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 103577-45-3 REGISTRY

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (±)-Lansoprazole

CN 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole


CN A 65006

CN AG 1749

CN Agopton

CN Ilsatec

CN Ketian
 CN Lancid
 CN Lanfast
 CN Lanproton
 CN Lansopep
 CN **Lansoprazole**
 CN Lanston
 CN Lanz
 CN Lanzol 30
 CN Lanzopral
 CN Lanzor
 CN Ogastro
 CN PP/K-10
 CN Prevacid
 CN Promp
 CN Prosogan
 CN Suprecid
 CN Takepron
 CN Ulpax
 CN Zoton
 FS 3D CONCORD
 DR 154727-72-7
 MF C16 H14 F3 N3 O2 S
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
 CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES,
 EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER,
 USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

738 REFERENCES IN FILE CA (1967 TO DATE)
 10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 740 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.96	40.43

FILE 'USPATFULL' ENTERED AT 20:26:44 ON 11 AUG 2002
 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 8 Aug 2002 (20020808/PD)
 FILE LAST UPDATED: 8 Aug 2002 (20020808/ED)
 HIGHEST GRANTED PATENT NUMBER: US6430743
 HIGHEST APPLICATION PUBLICATION NUMBER: US2002108159
 CA INDEXING IS CURRENT THROUGH 8 Aug 2002 (20020808/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 8 Aug 2002 (20020808/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2002
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2002

```
>>> USPAT2 is now available.  USPATFULL contains full text of the  <<<
>>> original, i.e., the earliest published granted patents or  <<<
>>> applications.  USPAT2 contains full text of the latest US  <<<
>>> publications, starting in 2001, for the inventions covered in  <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent  <<<
>>> publications.  The publication number, patent kind code, and  <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.  <<<

>>> USPATFULL and USPAT2 can be accessed and searched together  <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to  <<<
>>> enter this cluster.  <<<
>>> Use USPATALL when searching terms such as patent assignees,  <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.  <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

```
(FILE 'HOME' ENTERED AT 20:23:32 ON 11 AUG 2002)

FILE 'REGISTRY' ENTERED AT 20:23:39 ON 11 AUG 2002
      E OMEPRAZOLE/CN
L1      1 S E3

FILE 'HCAPLUS' ENTERED AT 20:25:06 ON 11 AUG 2002
L2      2172 S L1
L3      1814 S L2 AND PD < MARCH 2000

FILE 'USPATFULL' ENTERED AT 20:25:39 ON 11 AUG 2002
L4      210 S L1
L5      109 S L4 AND PD < MARCH 2000

FILE 'REGISTRY' ENTERED AT 20:26:27 ON 11 AUG 2002
      E LANSOPRAZOLE/CN
L6      1 S E3

FILE 'USPATFULL' ENTERED AT 20:26:44 ON 11 AUG 2002
```

```
=> s 16 and pd < march 2000
      115 L6
      2624453 PD < MARCH 2000
      (PD<20000300)
L7      52 L6 AND PD < MARCH 2000
```

=> d 17, ibib abs fhitr, 1-5

L7 ANSWER 1 OF 52 USPATFULL

Full Text	Citing References
-----------	-------------------

```
ACCESSION NUMBER: 2002:115818 USPATFULL
TITLE:            Pharmaceutical formulation comprising a 2-
                  [(2-pyridinyl) methyl] sulfinyl benzimidazole having
                  anti-ulcer activity and a process for the preparation
                  of such formulation
INVENTOR(S):      Henriksen, Kristian Lund, S.o slashed.borg, DENMARK
                  Kann, Helle, Frederiksberg, DENMARK
                  S.o slashed.rensen, Karen Eichstedt, Valby, DENMARK
```

PATENT ASSIGNEE(S): Pedersen, S.o slashed.ren Bols, Hvidovre, DENMARK
A/S GEA Farmaceutisk Fabrik, Frederiksberg, DENMARK
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391342	B1	20020521
	WO 9948498		19990930
APPLICATION INFO.:	US 2000-646486		20000919 (9)
	<u>WO 1999-DK137</u>		19990317
			20000919 PCT 371 date


	NUMBER	DATE
PRIORITY INFORMATION:	DK 1998-397	19980320
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Bennett, Rachel M.	
LEGAL REPRESENTATIVE:	Cohen, Pontani, Lieberman & Pavane	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	763	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Oral pharmaceutical formulation comprising granules having an inert core coated with a layer, comprising a 2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, a separating layer and an enteric coating layer, and a process for the preparation of such formulation using a melt coating technique for the preparation of the benzimidazole containing layer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **103577-45-3**, Lansoprazole
(pharmaceuticals comprising a 2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having antiulcer activity)
RN 103577-45-3 USPATFULL
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 52 USPATFULL

Full Text Citing References


ACCESSION NUMBER: 2002:102067 USPATFULL
TITLE: Suppository form comprising an acid-labile active compound
INVENTOR(S): Linder, Rudolf, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Dietrich, Rango, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6383510	B1	20020507
	WO 9929299		19990617

APPLICATION INFO.: US 2000-554079 20000706 (9)
 WO 1998-EP7946 19981208
 20000706 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19754324	19971208
	DE 1998-19822549	19980520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
ASSISTANT EXAMINER:	Bennett, Rachel M.	
LEGAL REPRESENTATIVE:	Jacobson Holman, PLLC	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	577	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT **103577-45-3**, Lansoprazole
 (oral administration form contg. acid-labile active agent)
 RN **103577-45-3** USPATFULL
 CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 52 USPATFULL

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2002:63891 USPATFULL
 TITLE: Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
 INVENTOR(S): Fujii, Kenji, Akashi, JAPAN
 Yamashita, Katsuji, Kobe, JAPAN
 Hosoe, Kazunori, Takasago, JAPAN
 Hidaka, Takayoshi, Kobe, JAPAN
 PATENT ASSIGNEE(S): Kaneka Corporation, Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362169	B1	20020326
	WO 9943327		19990902
APPLICATION INFO.:	US 2000-622712		20000822 (9)
	WO 1999-JP717		19990217
			20000822 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-42418	19980224
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Weddington, Kevin E.	
LEGAL REPRESENTATIVE:	Armstrong, Westerman & Hattori, LLP	


NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
 LINE COUNT: 583

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antibacterial compositions comprising (1) a rifamycin derivative represented by the formula (I) or its physiologically acceptable salt, and (2) a proton pump inhibitor (a) or a bismuth preparation (b) wherein the components (1) and (2) are used in such amounts as producing a synergistic effect against Helicobacter pylori, drugs and remedies for digestive organ diseases which contain the antibacterial compositions, process for producing them, and pharmaceutical preparations related to the antibacterial compositions. The compositions can be administered to patients with digestive diseases caused by infection of Helicobacter pylori in a smaller dose and at a lower administration frequency as compared with conventional remedies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 103577-45-3, Lansoprazole
 (antimicrobial compns. contg. rifamycin derivs. with synergistic effect, drugs and remedies for digestive diseases contg. the same, process for the prodn. thereof and preps. assocd. therewith)
 RN 103577-45-3 USPATFULL
 CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 52 USPATFULL

Full Text Claim References

ACCESSION NUMBER: 2002:39675 USPATFULL
 TITLE: Double capsule for the administration of active principles in multiple therapies
 INVENTOR(S): Sanso, Giovanni, Milan, ITALY
 PATENT ASSIGNEE(S): Axcan Pharma Inc., Quebec, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6350468	B1	20020226
	<u>WO 9930693</u>		19990624
APPLICATION INFO.:	US 2000-581721		20000616 (9)
	<u>WO 1998-EP8167</u>		19981214
			20000616 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1997-MI2788	19971217
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Bennett, Rachel M.	
LEGAL REPRESENTATIVE:	Myers Bigel Sibley & Sajovec P.A.	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	710	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical dosage form particularly suitable for the administration of active principles in multiple therapies is disclosed. The pharmaceutical dosage form is a double capsule where in an internal capsule is placed inside an external one. Each internal and external capsule includes one or more active principles. A double capsule according to the invention is preferably used in triple or quadruple therapies against the microorganisms *Helicobacter Pylori*. Advantages of this pharmaceutical dosage form consist in providing a simple posology for administration of two and more active principles, allowing the active principles to activate at the right intervals of time and in the preestablished quantities, and preventing interactions between active principles. In a preferred embodiment of the invention, the pharmaceutical dosage form has an external capsule containing bismuth subcitrate and metronidazole, and an internal capsule containing tetracycline and optionally omeprazole, which is used in therapy for eradication of *Helicobacter pylori*.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **103577-45-3**, Lansoprazole

(double capsules for administration of active principles in multiple therapies against *Helicobacter pylori*)

RN **103577-45-3** USPATFULL

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 52 USPATFULL



ACCESSION NUMBER: 2001:226274 USPATFULL
 TITLE: Orally disintegrable tablets
 INVENTOR(S): Shimizu, Toshihiro, Itami, Japan
 Morimoto, Shuji, Suita, Japan
 Tabata, Tetsuro, Suita, Japan
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6328994	B1	20011211
	WO 9959544		19991125
APPLICATION INFO.:	US 1999-355781		19990804 (9)
	WO 1999-JP2548		19990517
			19990804 PCT 371 date
			19990804 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-135472	19980518
	JP 1998-219266	19980803
	JP 1998-222151	19980805
	JP 1998-344810	19981029
	JP 1999-5144	19990112
	JP 1999-15851	19990125

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Page, Thurman K.
 ASSISTANT EXAMINER: Tran, S.


LEGAL REPRESENTATIVE: Chao, Mark, Ramesh, Elaine M.
 NUMBER OF CLAIMS: 45
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2214

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μ m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 103577-45-3, Lansoprazole
 (orally disintegrable tablets contg. enteric coated fine granules of acid-labile drugs)
 RN 103577-45-3 USPATFULL
 CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



=> file re

'RE' IS AN AMBIGUOUS FILE OR CLUSTER NAME
 REACTION - Reactions Cluster
 RESEARCH - Research Cluster
 REGISTRY - The CAS Registry File of substances

ENTER FILE OR CLUSTER NAME (IGNORE):file reg

'FILE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):e pantoprazole/cn

'E0' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):end

=> e pantoprazole/cn

'CN' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'USPATFULL'

The indicated field code is not available for EXPAND in this file. To see a list of valid EXPAND field codes, enter HELP SFIELDS at an arrow prompt (=>).

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	26.99	67.42

FILE 'REGISTRY' ENTERED AT 20:28:13 ON 11 AUG 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4
 DICTIONARY FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
 for more information. See STNote 27, Searching Properties in the CAS
 Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e pantoprazole/cn

E1 1 PANTOPHYSIN (RAT CLONE PPH.RN)/CN
 E2 1 PANTOPON/CN
 E3 1 --> PANTOPRAZOLE/CN
 E4 1 PANTOPRAZOLE SODIUM/CN
 E5 1 PANTOPRAZOLE SODIUM HYDRATE/CN
 E6 1 PANTOPRAZOLE SODIUM SESQUIHYDRATE/CN
 E7 1 PANTOPRIM/CN
 E8 1 PANTOPUR/CN
 E9 1 PANTOPYRANOID A/CN
 E10 1 PANTOPYRANOID B/CN
 E11 1 PANTOPYRANOID C/CN
 E12 1 PANTOSAL-GLUCOSID/CN

=> s e3

L8 1 PANTOPRAZOLE/CN

=> d l8

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 102625-70-7 REGISTRY

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-
 pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-
 benzimidazole

CN BY 1023

CN **Pantoprazole**

CN SKF 96022

FS 3D CONCORD

DR 154644-14-1

MF C16 H15 F2 N3 O4 S


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
 CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES,
 EMBASE, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, RTECS*, SYNTHLINE,
 TOXCENTER, USAN, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

326 REFERENCES IN FILE CA (1967 TO DATE)
 11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 329 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.96	73.38

FILE 'USPATFULL' ENTERED AT 20:28:31 ON 11 AUG 2002
 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 8 Aug 2002 (20020808/PD)
 FILE LAST UPDATED: 8 Aug 2002 (20020808/ED)
 HIGHEST GRANTED PATENT NUMBER: US6430743
 HIGHEST APPLICATION PUBLICATION NUMBER: US2002108159
 CA INDEXING IS CURRENT THROUGH 8 Aug 2002 (20020808/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 8 Aug 2002 (20020808/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2002
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
 >>> original, i.e., the earliest published granted patents or <<<
 >>> applications. USPAT2 contains full text of the latest US <<<
 >>> publications, starting in 2001, for the inventions covered in <<<
 >>> USPATFULL. A USPATFULL record contains not only the original <<<
 >>> published document but also a list of any subsequent <<<
 >>> publications. The publication number, patent kind code, and <<<
 >>> publication date for all the US publications for an invention <<<
 >>> are displayed in the PI (Patent Information) field of USPATFULL <<<
 >>> records and may be searched in standard search fields, e.g., /PN, <<<
 >>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
 >>> through the new cluster USPATALL. Type FILE USPATALL to <<<
 >>> enter this cluster. <<<
 >>> <<<
 >>> Use USPATALL when searching terms such as patent assignees, <<<
 >>> classifications, or claims, that may potentially change from <<<
 >>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d his

(FILE 'HOME' ENTERED AT 20:23:32 ON 11 AUG 2002)

FILE 'REGISTRY' ENTERED AT 20:23:39 ON 11 AUG 2002
 E OMEPRAZOLE/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 20:25:06 ON 11 AUG 2002

L2 2172 S L1

L3 1814 S L2 AND PD < MARCH 2000

FILE 'USPATFULL' ENTERED AT 20:25:39 ON 11 AUG 2002
 L4 210 S L1
 L5 109 S L4 AND PD < MARCH 2000

FILE 'REGISTRY' ENTERED AT 20:26:27 ON 11 AUG 2002
 E LANSOPRAZOLE/CN
 L6 1 S E3

FILE 'USPATFULL' ENTERED AT 20:26:44 ON 11 AUG 2002
 L7 52 S L6 AND PD < MARCH 2000

FILE 'REGISTRY' ENTERED AT 20:28:13 ON 11 AUG 2002
 E PANTOPRAZOLE/CN
 L8 1 S E3

FILE 'USPATFULL' ENTERED AT 20:28:31 ON 11 AUG 2002

=> s 18

L9 48 L8

=> s 19 and pd < march 2000
 2624453 PD < MARCH 2000
 (PD<20000300)

L10 22 L9 AND PD < MARCH 2000

=> d 110, 1-5

L10 ANSWER 1 OF 22 USPATFULL

	Full Text	Citing References
AN	2002:115818	USPATFULL
TI	Pharmaceutical formulation comprising a 2- [(2-pyridinyl) methyl] sulfinyl benzimidazole having anti-ulcer activity and a process for the preparation of such formulation	
IN	Henriksen, Kristian Lund, S.o slashed.borg, DENMARK Kann, Helle, Frederiksberg, DENMARK S.o slashed.rensen, Karen Eichstedt, Valby, DENMARK Pedersen, S.o slashed.ren Bols, Hvidovre, DENMARK	
PA	A/S GEA Farmaceutisk Fabrik, Frederiksberg, DENMARK (non-U.S. corporation)	
PI	US 6391342	B1 20020521
	WO 9948498 19990930	
AI	US 2000-646486	20000919 (9)
	WO 1999-DK137	19990317
		20000919 PCT 371 date
PRAI	DK 1998-397	19980320
DT	Utility	
FS	GRANTED	
LN.CNT	763	
INCL	INCLM: 424/490.000 INCLS: 424/457.000; 424/458.000; 424/456.000; 424/489.000; 424/498.000	
NCL	NCLM: 424/490.000 NCLS: 424/456.000; 424/457.000; 424/458.000; 424/489.000; 424/498.000	
IC	[7] ICM: A61K009-50 ICS: A61K009-16; A61K009-52; A61K009-64; A61K009-54	
EXF	424/490; 424/457; 424/458; 424/456; 424/502; 424/489	
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	

L10 ANSWER 2 OF 22 USPATFULL

	Full Text	Citing References
AN	2002:115775	USPATFULL

TI In situ formation of polymeric material
 IN Dettmar, Peter William, Hull, UNITED KINGDOM
 Jolliffe, Ian Gordon, Hull, UNITED KINGDOM
 Skaugrud, Oyvind, Mjoendalen, NORWAY
 PA Reckitt Benckiser Healthcare (UK) Limited, Slough, UNITED KINGDOM
 (non-U.S. corporation)
PI US 6391294 B1 20020521
WO 9909962 19990304
AI US 2000-485771 20000412 (9)
 WO 1998-GB2410 19980810
 20000412 PCT 371 date
PRAI GB 1997-17626 19970821
 GB 1997-17627 19970821
 DT Utility
 FS GRANTED
 LN.CNT 865
 INCL INCLM: 424/078.110
 INCLS: 424/078.080; 424/484.000; 424/486.000; 424/487.000; 424/488.000;
 424/400.000; 514/772.000; 514/772.100
 NCL NCLM: 424/078.110
 NCLS: 424/078.080; 424/400.000; 424/484.000; 424/486.000; 424/487.000;
 424/488.000; 514/772.000; 514/772.100
 IC [7]
 ICM: A61K031-74
 EXF 424/78.4; 424/78.17; 424/78.08; 424/484; 424/486; 424/487; 424/488;
 424/400; 514/772
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 22 USPATFULL

Full Text	Citing References
--------------	----------------------

AN 2002:102067 USPATFULL
 TI Suppository form comprising an acid-labile active compound
 IN Linder, Rudolf, Konstanz, GERMANY, FEDERAL REPUBLIC OF
 Dietrich, Rango, Konstanz, GERMANY, FEDERAL REPUBLIC OF
 PA Byk Gulden Lomberg Chemische Fabrik GmbH, Konstanz, GERMANY, FEDERAL
 REPUBLIC OF (non-U.S. corporation)
PI US 6383510 B1 20020507
WO 9929299 19990617
AI US 2000-554079 20000706 (9)
 WO 1998-EP7946 19981208
 20000706 PCT 371 date
PRAI DE 1997-19754324 19971208
 DE 1998-19822549 19980520
 DT Utility
 FS GRANTED
 LN.CNT 577
 INCL INCLM: 424/436.000
 INCLS: 424/434.000
 NCL NCLM: 424/436.000
 NCLS: 424/434.000
 IC [7]
 ICM: A61F013-00
 ICS: A61F009-02
 EXF 424/434; 424/436; 514/338
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 22 USPATFULL

Full Text	Citing References
--------------	----------------------

AN 2002:63891 USPATFULL
 TI Antibacterial compositions with synergistic effect, drugs and remedies
 for digestive diseases containing the same, process for the production
 thereof and preparations associated therewith

IN Fujii, Kenji, Akashi, JAPAN
 Yamashita, Katsuji, Kobe, JAPAN
 Hosoe, Kazunori, Takasago, JAPAN
 Hidaka, Takayoshi, Kobe, JAPAN
 PA Kaneka Corporation, Osaka, JAPAN (non-U.S. corporation)
 PI US 6362169 B1 20020326
WO 9943327 19990902
 AI US 2000-622712 20000822 (9)
WO 1999-JP717 19990217
 20000822 PCT 371 date
 PRAI JP 1998-42418 19980224
 DT Utility
 FS GRANTED
 LN.CNT 583
 INCL INCLM: 514/030.000
 INCLS: 514/394.000; 514/395.000; 424/653.000
 NCL NCLM: 514/030.000
 NCLS: 424/653.000; 514/394.000; 514/395.000
 IC [7]
 ICM: A61K031-70
 ICS: A61K031-415; A61K033-24
 EXF 514/30; 514/394; 514/395; 424/653
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 22 USPATFULL

Full Text	Citing References
--------------	----------------------

AN 2002:39675 USPATFULL
 TI Double capsule for the administration of active principles in multiple
 therapies
 IN Sanso, Giovanni, Milan, ITALY
 PA Axcen Pharma Inc., Quebec, CANADA (non-U.S. corporation)
 PI US 6350468 B1 20020226
WO 9930693 19990624
 AI US 2000-581721 20000616 (9)
WO 1998-EP8167 19981214
 20000616 PCT 371 date
 PRAI IT 1997-MI2788 19971217
 DT Utility
 FS GRANTED
 LN.CNT 710
 INCL INCLM: 424/456.000
 INCLS: 424/451.000; 424/453.000; 424/454.000
 NCL NCLM: 424/456.000
 NCLS: 424/451.000; 424/453.000; 424/454.000
 IC [7]
 ICM: A61K009-64
 ICS: A61K009-48
 EXF 424/451; 424/453; 424/454; 424/456; 424/460
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.38	78.76

FILE 'REGISTRY' ENTERED AT 20:29:03 ON 11 AUG 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4
 DICTIONARY FILE UPDATES: 9 AUG 2002 HIGHEST RN 443534-23-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e rabeprazole/cn

E1	1	RABENOSYN-5 (HUMAN)/CN
E2	1	RABENZAZOLE/CN
E3	1	--> RABEPRAZOLE/CN
E4	1	RABEPRAZOLE SODIUM/CN
E5	1	RABEPRAZOLE-TH/CN
E6	1	RABI(S) BLACK 6/CN
E7	1	RABI(S) MAROON OH/CN
E8	1	RABI(S) OCHER TY/CN
E9	1	RABIB4 PROTEIN (MOUSE CLONE I1 GENE RABIP4 N-TERMINAL FRAGME NT)/CN
E10	1	RABIDANOL/CN
E11	1	RABISAN/CN
E12	1	RABISAN, MIXT. CONTG./CN

=> s e3

L11 1 RABEPRAZOLE/CN

=> d l11

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 117976-89-3 REGISTRY

CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-[[[3-Methyl-4-(3-methoxypropoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole

CN 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]benzimidazole

CN LY 307640

CN **Rabeprazole**

FS 3D CONCORD

MF C18 H21 N3 O3 S


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

172 REFERENCES IN FILE CA (1967 TO DATE)
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 173 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.96	84.72

FILE 'USPATFULL' ENTERED AT 20:29:22 ON 11 AUG 2002
 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 8 Aug 2002 (20020808/PD)
 FILE LAST UPDATED: 8 Aug 2002 (20020808/ED)
 HIGHEST GRANTED PATENT NUMBER: US6430743
 HIGHEST APPLICATION PUBLICATION NUMBER: US2002108159
 CA INDEXING IS CURRENT THROUGH 8 Aug 2002 (20020808/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 8 Aug 2002 (20020808/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2002
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2002

```
>>> USPAT2 is now available.  USPATFULL contains full text of the  <<<
>>> original, i.e., the earliest published granted patents or  <<<
>>> applications.  USPAT2 contains full text of the latest US  <<<
>>> publications, starting in 2001, for the inventions covered in  <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent  <<<
>>> publications.  The publication number, patent kind code, and  <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.  <<<
```

```
>>> USPATFULL and USPAT2 can be accessed and searched together  <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to  <<<
>>> enter this cluster.  <<<
>>>  <<<
>>> Use USPATALL when searching terms such as patent assignees,  <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.  <<<
```

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d his

(FILE 'HOME' ENTERED AT 20:23:32 ON 11 AUG 2002)

FILE 'REGISTRY' ENTERED AT 20:23:39 ON 11 AUG 2002
 E OMEPRAZOLE/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 20:25:06 ON 11 AUG 2002

L2 2172 S L1

L3 1814 S L2 AND PD < MARCH 2000

FILE 'USPATFULL' ENTERED AT 20:25:39 ON 11 AUG 2002

L4 210 S L1

L5 109 S L4 AND PD < MARCH 2000

FILE 'REGISTRY' ENTERED AT 20:26:27 ON 11 AUG 2002

E LANSOPRAZOLE/CN

L6 1 S E3

L7 FILE 'USPATFULL' ENTERED AT 20:26:44 ON 11 AUG 2002
52 S L6 AND PD < MARCH 2000

L8 FILE 'REGISTRY' ENTERED AT 20:28:13 ON 11 AUG 2002
E PANTOPRAZOLE/CN
1 S E3

L9 FILE 'USPATFULL' ENTERED AT 20:28:31 ON 11 AUG 2002
48 S L8
L10 22 S L9 AND PD < MARCH 2000

L11 FILE 'REGISTRY' ENTERED AT 20:29:03 ON 11 AUG 2002
E RABEPRAZOLE/CN
1 S E3

FILE 'USPATFULL' ENTERED AT 20:29:22 ON 11 AUG 2002

=>

=> s l11

L12 35 L11

=> s l12 and pd < march 2000
2624453 PD < MARCH 2000
(PD<20000300)

L13 15 L12 AND PD < MARCH 2000

=> d l13, ibib abs fhitr, 1-5

L13 ANSWER 1 OF 15 USPATFULL

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2002:102067 USPATFULL
TITLE: Suppository form comprising an acid-labile active compound
INVENTOR(S): Linder, Rudolf, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Dietrich, Rango, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Konstanz,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6383510	B1	20020507
	WO 9929299		19990617
APPLICATION INFO.:	US 2000-554079		20000706 (9)
	WO 1998-EP7946		19981208
			20000706 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19754324	19971208
	DE 1998-19822549	19980520

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kishore, Gollamudi S.
ASSISTANT EXAMINER: Bennett, Rachel M.
LEGAL REPRESENTATIVE: Jacobson Holman, PLLC
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Acid-labile active compounds are prepared in suppository form,
particularly for rectal administration.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **117976-89-3**, Rabeprazole

(oral administration form contg. acid-labile active agent)

RN **117976-89-3** USPATFULL

CN **1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-** (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 15 USPATFULL



ACCESSION NUMBER: 2002:39675 USPATFULL
 TITLE: Double capsule for the administration of active principles in multiple therapies
 INVENTOR(S): Sanso, Giovanni, Milan, ITALY
 PATENT ASSIGNEE(S): Axcan Pharma Inc., Quebec, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6350468	B1	20020226
	WO 9930693		19990624
APPLICATION INFO.:	US 2000-581721		20000616 (9)
	<u>WO 1998-EP8167</u>		19981214
			20000616 PCT 371 date


	NUMBER	DATE
PRIORITY INFORMATION:	<u>IT 1997-MI2788</u>	19971217
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Bennett, Rachel M.	
LEGAL REPRESENTATIVE:	Myers Bigel Sibley & Sajovec P.A.	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	710	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical dosage form particularly suitable for the administration of active principles in multiple therapies is disclosed. The pharmaceutical dosage form is a double capsule where in an internal capsule is placed inside an external one. Each internal and external capsule includes one or more active principles. A double capsule according to the invention is preferably used in triple or quadruple therapies against the microorganisms *Helicobacter Pylori*. Advantages of this pharmaceutical dosage form consist in providing a simple posology for administration of two and more active principles, allowing the active principles to activate at the right intervals of time and in the preestablished quantities, and preventing interactions between active principles. In a preferred embodiment of the invention, the pharmaceutical dosage form has an external capsule containing bismuth subcitrate and metronidazole, and an internal capsule containing tetracycline and optionally omeprazole, which is used in therapy for eradication of *Helicobacter pylori*.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **117976-89-3**, Rabeprazole
 (double capsules for administration of active principles in multiple
 therapies against Helicobacter pylori)
 RN 117976-89-3 USPATFULL
 CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-
 pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 15 USPATFULL

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2001:226273 USPATFULL
 TITLE: Oral administration form for an acid liable active
 proton pump inhibitor
 INVENTOR(S): Linder, Rudolf, Konstanz, Germany, Federal Republic of
 Dietrich, Rango, Konstanz, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Konstanz,
 Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6328993	B1	20011211
	WO 9929320		19990617
APPLICATION INFO.:	US 2000-530944		20000622 (9)
	WO 1998-EP8036		19981208
			20000622 PCT 371 date
			20000622 PCT 102(e) date


	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19754324	19971208
	DE 1998-19822549	19980520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Bennett, Rachel M.	
LEGAL REPRESENTATIVE:	Jacobson Holman, PLLC	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
LINE COUNT:	656	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel administration form for acid-labile active compounds are
 described. The novel administration forms have no enteric layers and are
 suitable for oral administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **117976-89-3**, Rabeprazole
 (oral administration form contg. acid-labile active agent)
 RN 117976-89-3 USPATFULL
 CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-
 pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 4 OF 15 USPATFULL

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2001:179136 USPATFULL
 TITLE: Proton pump inhibitor in therapeutic combination with antibacterial substances
 INVENTOR(S): Tuch, Klaus, Ahrensburg, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303644	B1	20011016
	WO 9904816		19990204
APPLICATION INFO.:	US 2000-463390		20000127 (9)
	WO 1998-EP4553		19980721
			20000127 PCT 371 date
			20000127 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1997-112795	19970725
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Weddington, Kevin E.	
LEGAL REPRESENTATIVE:	Jacobson Holman, PLLC	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	260	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to the use of proton pump inhibitors as combination therapeutics in the treatment of bacterial diseases which do not affect the gastrointestinal track using antibacterially active compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **117976-89-3**, Rabeprazole
 (proton pump inhibitor in therapeutic combination with antibacterial substances)

RN 117976-89-3 USPATFULL

CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 15 USPATFULL

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2001:43756 USPATFULL
 TITLE: Composition containing an acid-labile omeprazole and process for its preparation
 INVENTOR(S): Seth, Pawan, Irvine, CA, United States
 PATENT ASSIGNEE(S): Schwarz Pharma AG, Monheim, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207198	B1	20010327
	WO 9712581		19970410
APPLICATION INFO.:	US 1998-43145		19980803 (9)
	<u>WO 1996-IB1055</u>		19960923
			19980803 PCT 371 date
			19980803 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1995-11094	19950921
	FR 1995-14492	19951207
	FR 1996-2265	19960223
	FR 1996-5082	19960423


DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Page, Thurman K.
 ASSISTANT EXAMINER: Seidleck, Brian K.
 LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
 NUMBER OF CLAIMS: 29
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
 LINE COUNT: 1170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition, particularly adapted for oral administration, containing omeprazole, and a method for preparing the composition, are disclosed. The composition, being exempt of alkaline-reacting compounds, contains a core constituted of nuclei and said benzimidazole, the nuclei and benzimidazole being compressed together, an intermediate layer, and an enteric layer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **117976-89-3**
 (enteric-coated oral compns. contg. acid-labile benzimidazoles)
 RN 117976-89-3 USPATFULL
 CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

25.78

110.50

STN INTERNATIONAL LOGOFF AT 20:30:10 ON 11 AUG 2002

